| http://www.w3.org/ns/prov#value | - Advise the patient that liver function tests may be monitored during treatment.17.2 HypersensitivityInform the patient that anaphylactic reactions, including shock were reported with ERAXIS. Inform the patient if these reactions occur, ERAXIS may be discontinued and appropriate treatment administered.Inform the patient that ERAXIS is also known to cause infusion-related adverse reactions, possibly
|
